Feature

Beyond IOP: The Mood Effects of CAIs

Evidence from large US dataset suggests topical carbonic Anhydrase Inhibitors may increase depression risk in glaucoma patients

  • By

  • March 12, 2026

  • 5 min

Share

  • 1

    Carbonic anhydrase inhibitors (CAIs) are used in glaucoma treatment.

  • 2

    Study shows CAIs may increase depression/anxiety in patients.

  • 3

    Stronger link found than expected for a topical treatment.

  • 4

    Importance of monitoring mood symptoms post-treatment initiation.

  • 5

    Automated EHR tools can enhance patient screening for psychiatric distress.

Original Source(s)

Beyond IOP: The Mood Effects of CAIs

Evidence from large US dataset suggests topical carbonic Anhydrase Inhibitors may increase depression risk in glaucoma patients

  • March 12, 2026

  • 5 min

Related Content

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

The Most Influential Conversations in Ophthalmology Aren’t on the Podium

How WhatsApp is quietly shaping clinical practice

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.